Cargando…

Real-Life Experience with Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Virus Infection with Genotypes 1 and 4 in Children Aged 12 to 17 Years—Results of the POLAC Project

Background: Available real-world data on the efficacy and safety of ledipasvir/sofosbuvir (LDV/SOF) in pediatric patients are limited. In this prospective, open-label, single-center study, we aimed to present our real-life experience with a fixed dose of LDV/SOF (90/400 mg) for the treatment of chro...

Descripción completa

Detalles Bibliográficos
Autores principales: Pokorska-Śpiewak, Maria, Dobrzeniecka, Anna, Aniszewska, Małgorzata, Marczyńska, Magdalena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465669/
https://www.ncbi.nlm.nih.gov/pubmed/34575286
http://dx.doi.org/10.3390/jcm10184176
_version_ 1784572935345799168
author Pokorska-Śpiewak, Maria
Dobrzeniecka, Anna
Aniszewska, Małgorzata
Marczyńska, Magdalena
author_facet Pokorska-Śpiewak, Maria
Dobrzeniecka, Anna
Aniszewska, Małgorzata
Marczyńska, Magdalena
author_sort Pokorska-Śpiewak, Maria
collection PubMed
description Background: Available real-world data on the efficacy and safety of ledipasvir/sofosbuvir (LDV/SOF) in pediatric patients are limited. In this prospective, open-label, single-center study, we aimed to present our real-life experience with a fixed dose of LDV/SOF (90/400 mg) for the treatment of chronic hepatitis C (CHC) genotypes 1 and 4 in children aged 12 to 17 years. Methods: We analyzed intention-to-treat (ITT) and per-protocol (PP) rates of sustained virological response (SVR), defined as undetectable HCV viral load at posttreatment week 12, in 37 participants treated with LDV/SOF according to the HCV genotype, baseline liver fibrosis, duration of treatment, and experience of the previous ineffective antiviral treatment. There were 32 patients infected with genotype 1 and 5 with genotype 4. Fourteen (38%) participants were treatment-experienced, two were coinfected with HIV, and three were cirrhotic. Two patients qualified for 24 weeks of therapy, and the remaining 35 received 12 weeks of LDV/SOF treatment. Results: The overall ITT SVR12 rate was 36/37 (97%). One patient was lost to follow-up after week 4 of therapy when his HCV RNA was undetectable. All 36 patients who completed the full protocol achieved SVR (36/36, 100%). PP analyses of SVR12 rates according to the HCV genotype, baseline liver fibrosis, duration of the treatment, and previous ineffective treatment were all 100%. A significant decrease in aminotransferase serum levels was observed in the subsequent weeks of the treatment and at SVR assessment compared to baseline. No serious adverse events were reported. Conclusions: The results of this study confirm previous observations of a suitable efficacy and safety profile of LDV/SOF for the treatment of CHC genotypes 1 and 4 in adolescents.
format Online
Article
Text
id pubmed-8465669
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84656692021-09-27 Real-Life Experience with Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Virus Infection with Genotypes 1 and 4 in Children Aged 12 to 17 Years—Results of the POLAC Project Pokorska-Śpiewak, Maria Dobrzeniecka, Anna Aniszewska, Małgorzata Marczyńska, Magdalena J Clin Med Article Background: Available real-world data on the efficacy and safety of ledipasvir/sofosbuvir (LDV/SOF) in pediatric patients are limited. In this prospective, open-label, single-center study, we aimed to present our real-life experience with a fixed dose of LDV/SOF (90/400 mg) for the treatment of chronic hepatitis C (CHC) genotypes 1 and 4 in children aged 12 to 17 years. Methods: We analyzed intention-to-treat (ITT) and per-protocol (PP) rates of sustained virological response (SVR), defined as undetectable HCV viral load at posttreatment week 12, in 37 participants treated with LDV/SOF according to the HCV genotype, baseline liver fibrosis, duration of treatment, and experience of the previous ineffective antiviral treatment. There were 32 patients infected with genotype 1 and 5 with genotype 4. Fourteen (38%) participants were treatment-experienced, two were coinfected with HIV, and three were cirrhotic. Two patients qualified for 24 weeks of therapy, and the remaining 35 received 12 weeks of LDV/SOF treatment. Results: The overall ITT SVR12 rate was 36/37 (97%). One patient was lost to follow-up after week 4 of therapy when his HCV RNA was undetectable. All 36 patients who completed the full protocol achieved SVR (36/36, 100%). PP analyses of SVR12 rates according to the HCV genotype, baseline liver fibrosis, duration of the treatment, and previous ineffective treatment were all 100%. A significant decrease in aminotransferase serum levels was observed in the subsequent weeks of the treatment and at SVR assessment compared to baseline. No serious adverse events were reported. Conclusions: The results of this study confirm previous observations of a suitable efficacy and safety profile of LDV/SOF for the treatment of CHC genotypes 1 and 4 in adolescents. MDPI 2021-09-15 /pmc/articles/PMC8465669/ /pubmed/34575286 http://dx.doi.org/10.3390/jcm10184176 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Pokorska-Śpiewak, Maria
Dobrzeniecka, Anna
Aniszewska, Małgorzata
Marczyńska, Magdalena
Real-Life Experience with Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Virus Infection with Genotypes 1 and 4 in Children Aged 12 to 17 Years—Results of the POLAC Project
title Real-Life Experience with Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Virus Infection with Genotypes 1 and 4 in Children Aged 12 to 17 Years—Results of the POLAC Project
title_full Real-Life Experience with Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Virus Infection with Genotypes 1 and 4 in Children Aged 12 to 17 Years—Results of the POLAC Project
title_fullStr Real-Life Experience with Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Virus Infection with Genotypes 1 and 4 in Children Aged 12 to 17 Years—Results of the POLAC Project
title_full_unstemmed Real-Life Experience with Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Virus Infection with Genotypes 1 and 4 in Children Aged 12 to 17 Years—Results of the POLAC Project
title_short Real-Life Experience with Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Virus Infection with Genotypes 1 and 4 in Children Aged 12 to 17 Years—Results of the POLAC Project
title_sort real-life experience with ledipasvir/sofosbuvir for the treatment of chronic hepatitis c virus infection with genotypes 1 and 4 in children aged 12 to 17 years—results of the polac project
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465669/
https://www.ncbi.nlm.nih.gov/pubmed/34575286
http://dx.doi.org/10.3390/jcm10184176
work_keys_str_mv AT pokorskaspiewakmaria reallifeexperiencewithledipasvirsofosbuvirforthetreatmentofchronichepatitiscvirusinfectionwithgenotypes1and4inchildrenaged12to17yearsresultsofthepolacproject
AT dobrzenieckaanna reallifeexperiencewithledipasvirsofosbuvirforthetreatmentofchronichepatitiscvirusinfectionwithgenotypes1and4inchildrenaged12to17yearsresultsofthepolacproject
AT aniszewskamałgorzata reallifeexperiencewithledipasvirsofosbuvirforthetreatmentofchronichepatitiscvirusinfectionwithgenotypes1and4inchildrenaged12to17yearsresultsofthepolacproject
AT marczynskamagdalena reallifeexperiencewithledipasvirsofosbuvirforthetreatmentofchronichepatitiscvirusinfectionwithgenotypes1and4inchildrenaged12to17yearsresultsofthepolacproject